| Literature DB >> 19147228 |
Laurent Boissel1, Monica Betancur, Winfried S Wels, Hande Tuncer, Hans Klingemann.
Abstract
An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 +/- 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ B-ALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19147228 PMCID： PMC3047414 DOI： 10.1016/j.leukres.2008.11.024
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156